BC
FOLD

Bridgefront Capital’s Amicus Therapeutics FOLD Stock Holding History

Bridgefront Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,418
Closed -$192K – 612
2025
Q3 		$192K Sell
24,418
-25,483
-51% -$181K 0.06% 524
2025
Q2 		$286K Sell
49,901
-619
-1% -$4K 0.08% 444
2025
Q1 		$412K Buy
50,520
+2,780
+6% +$25.7K 0.12% 312
2024
Q4 		$450K Buy
47,740
+11,042
+30% +$115K 0.15% 232
2024
Q3 		$392K Buy
36,698
+25,715
+234% +$280K 0.15% 253
2024
Q2 		$109K Buy
+10,983
New +$113K 0.05% 448
2023
Q2 		– Sell
-13,122
Closed -$146K – 540
2023
Q1 		$146K Buy
+13,122
New +$162K 0.09% 370
2021
Q3 		– Sell
-12,641
Closed -$122K – 462
2021
Q2 		$122K Sell
12,641
-16,739
-57% -$163K 0.05% 546
2021
Q1 		$290K Buy
29,380
+13,040
+80% +$202K 0.09% 438
2020
Q4 		$377K Buy
+16,340
New +$334K 0.13% 291

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bridgefront Capital's FOLD Position: Q4 2025 in Review

Bridgefront Capital sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 24,418 shares — an estimated $192K sold.

Bridgefront Capital first reported a position in FOLD in Q4 2020 and held it in 10 quarters. The position peaked at $450K in Q4 2024. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Bridgefront Capital reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bridgefront Capital sold 24,418 Amicus Therapeutics shares in Q4 2025, an estimated $192K.
  • Bridgefront Capital first reported a position in Amicus Therapeutics in Q4 2020 and held it in 10 quarters.
  • Bridgefront Capital's Amicus Therapeutics position peaked at $450K in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.